Histopathological and clinical changes in patients with severe lupus nephritis treated with rituximab plus cyclophosphamide: A rebiopsy study in 7 patients

被引：0
|
作者：
Gunnarsson, I.
Sundelin, B.
Jonsdottir, T.
Jacobsson, S. H.
Welin-Henriksson, E.
Van Vollenhoven, R. F.
机构：
[1] Karolinska Univ Hosp, Stockholm, Sweden
[2] Danderyd Hosp, Stockholm, Sweden
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2006年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：64 / 64
页数：1
相关论文
共 50 条
  • [21] Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study
    Mónica Vigna-Perez
    Berenice Hernández-Castro
    Octavio Paredes-Saharopulos
    Diana Portales-Pérez
    Lourdes Baranda
    Carlos Abud-Mendoza
    Roberto González-Amaro
    Arthritis Research & Therapy, 8
  • [22] Adjusted Methylprednisolone Dosing to Serum Albumin Levels plus Cyclophosphamide in Patients with Lupus Nephritis. A Pilot Study
    Gonzalez-Diaz, V
    Gonzalez-Diaz, E.
    Martinez-Bonilla, G. E.
    Bernard-Medina, A. G.
    Gutierrez-Urena, S. R.
    Cerpa-Cruz, S.
    JOURNAL OF RHEUMATOLOGY, 2011, 38 (06) : 1204 - 1204
  • [23] A preliminary study of tacrolimus versus cyclophosphamide in patients with diffuse proliferative lupus nephritis
    Hong, Ren
    Haijin, Yu
    Xianglin, Wang
    Cuilan, Hao
    Nan, Chen
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 : 276 - 276
  • [24] Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study
    Moroni, Gabriella
    Raffiotta, Francesca
    Trezzi, Barbara
    Giglio, Elisa
    Mezzina, Nicoletta
    Del Papa, Nicoletta
    Meroni, Pierluigi
    Messa, Piergiorgio
    Sinico, Alberto Renato
    RHEUMATOLOGY, 2014, 53 (09) : 1570 - 1577
  • [25] Lupus nephritis in patients of Iranian origin: Differences in clinical and histopathological features at initial presentation
    Khajehdehi, P
    Rajaee, A
    Jalali, GAR
    Behzadi, S
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 1997, 12 (02) : 363 - 364
  • [26] Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone
    Cortés-Hernández, J
    Ordi-Ros, J
    Labrador, M
    Segarra, A
    Tovar, JL
    Balada, E
    Vilardell-Tarres, M
    LUPUS, 2003, 12 (04) : 287 - 296
  • [27] Clinical and histopathological features and short-term outcomes of lupus nephritis: a prospective study of 100 Egyptian patients
    Saleh, Mohammed
    Eltoraby, Ehab E.
    Tharwat, Samar
    Nassar, Mohammed Kamal
    LUPUS, 2020, 29 (08) : 993 - 1001
  • [28] Lupus nephritis patients treated with rituximab display reductions in both Anti-DNA and ENA Autoantibodies that parallel clinical responses
    Silverman, Gregg
    Jonsdottir, Thorunn
    Srikrishnan, Raj
    van Vollenhoven, Ronald F.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S563 - S564
  • [29] Impact of dosing strategy on clinical outcomes of patients with lupus nephritis initially treated with lower-than-recommended-dose cyclophosphamide
    Chienwichai, Kittiphan
    Choomnirat, Aniwat
    Sangkaew, Sorawat
    Sunanthamethee, Nutthapong
    Chang, Arunchai
    HELIYON, 2024, 10 (17)
  • [30] Electronmicroscopic resorption of immune deposits following rituximab treatment in membranous lupus nephritis: Biopsy-rebiopsy data from 4 patients.
    Gunnarsson, Iva
    Jonsdottir, Thorunn
    Sundelin, Birgitta
    Jacobson, Stefan H.
    van Vollenhoven, Ronald F.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S259 - S259
12345